New Zealand markets open in 3 hours 32 minutes

Aridis Pharmaceuticals, Inc. (ARDS)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0590-0.0055 (-8.53%)
As of 01:10PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.0645
Open0.0620
Bid0.0000 x 1000
Ask0.0000 x 1800
Day's range0.0560 - 0.0630
52-week range0.0500 - 0.5395
Volume148,384
Avg. volume97,733
Market cap2.63M
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-0.1600
Earnings date20 May 2024 - 24 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.00
  • GlobeNewswire

    Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

    LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum. The Annual Meeting has been adjo

  • GlobeNewswire

    Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

    Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023. Third Quarter Highlights

  • GlobeNewswire

    Aridis Pharmaceuticals Announces $2 Million Offering

    Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share